keyword
https://read.qxmd.com/read/38520274/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-and-suicidality-what-do-we-know-and-future-vistas
#21
EDITORIAL
Roger S McIntyre
No abstract text is available yet for this article.
March 23, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38518602/the-effects-of-fc-fusion-protein-glucagon-like-peptide-1-and-glucagon-dual-receptor-agonist-with-different-receptor-selectivity-in-vivo-studies
#22
JOURNAL ARTICLE
Peng Jiang, Ying Zeng, Wen Yang, Lijia Li, Linjun Zhou, Lin Xiao, Yong Li, Baohua Gu, Xiaoping Li, Jing Li, Wenjia Li, Linfeng Guo
BACKGROUND: Glucagon-like peptide-1 (GLP-1)/glucagon (GCG) dual receptor agonists with different receptor selectivity are under investigation and have shown significant improvement in both weight loss and glycemic control, but the optimal potency ratio between the two receptors to balance efficacy and safety remains unclear. EXPERIMENTAL APPROACH: We designed and constructed several dual receptor agonists with different receptor potency ratios using Fc fusion protein technology...
March 21, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38517864/repressing-mir-23a-promotes-the-transdifferentiation-of-pancreatic-%C3%AE-cells-to-%C3%AE-cells-via-negatively-regulating-the-expression-of-sdf-1%C3%AE
#23
JOURNAL ARTICLE
Hongmei Lang, Ning Lin, Xiaorong Chen, Jie Xiang, Xingping Zhang, Chao Kang
Pancreatic β-cell failure is a pathological feature in type 1 diabetes. One promising approach involves inducing transdifferentiation of related pancreatic cell types, specifically α cells that produce glucagon. The chemokine stromal cell-derived factor-1 alpha (SDF-1α) is implicated in pancreatic α-to-β like cell transition. Here, the serum level of SDF-1α was lower in T1D with C-peptide loss, the miR-23a was negatively correlated with SDF-1α. We discovered that exosomal miR-23a, secreted from β cells, functionally downregulates the expression of SDF-1α, leading to increased Pax4 expression and decreased Arx expression in vivo...
2024: PloS One
https://read.qxmd.com/read/38517522/comparing-major-and-mild-cognitive-impairment-risks-in-older-type-2-diabetic-patients-a-danish-register-based-study-on-dipeptidyl-peptidase-4-inhibitors-vs-glucagon-like-peptide-1-analogues
#24
JOURNAL ARTICLE
Vera Battini, Maria Antonietta Barbieri, Carla Carnovale, Edoardo Spina, Emilio Clementi, Maurizio Sessa
INTRODUCTION: The prevalence of major and mild cognitive impairment (CI) in type-2 diabetes older patients is 15-25% and 30-60%, respectively, thus affecting quality of life and health outcomes. There is, therefore, the need of head-to-head studies aiming at identifying the optimal treatment for individuals with type-2 diabetes at increased risk of mild and major CI. This study focuses on the risk of developing mild and major CI in Danish patients treated with dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 analogues (GLP-1a) using administrative and healthcare registers...
March 22, 2024: Journal of Neurology
https://read.qxmd.com/read/38516874/the-potential-for-improved-outcomes-in-the-prevention-and-therapy-of-diabetic-kidney-disease-through-stacking-of-drugs-from-different-classes
#25
REVIEW
David S H Bell, Terri Jerkins
Aggressive therapy of diabetic kidney disease (DKD) can not only slow the progression of DKD to renal failure but, if utilized at an early enough stage of DKD, can also stabilize and/or reverse the decline in renal function. The currently recognized standard of therapy for DKD is blockade of the renin-angiotensin system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). However, unless utilized at a very early stage, monotherapy with these drugs in DKD will only prevent or slow the progression of DKD and will neither stabilize nor reverse the progression of DKD to renal decompensation...
March 22, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38516742/next-generation-weight-loss-drugs-for-the-prevention-of-cancer
#26
JOURNAL ARTICLE
Chantelle Carbonell, Mariet Mathew Stephen, Yibing Ruan, Matthew T Warkentin, Darren R Brenner
Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers. Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention...
2024: Cancer Control: Journal of the Moffitt Cancer Center
https://read.qxmd.com/read/38515845/real-world-effectiveness-of-glp-1-receptor-agonist-based-treatment-strategies-on-time-in-range-in-patients-with-type-2-diabetes
#27
JOURNAL ARTICLE
Yongru Chen, Jingxian Chen, Shuo Zhang, Dan Zhu, Feiying Deng, Rui Zuo, Yufei Hu, Yue Zhao, Yale Duan, Benwei Lin, Fengwu Chen, Yun Liang, Jiaxiong Zheng, Barkat Ali Khan, Kaijian Hou
Background: Diabetes affects millions of people worldwide annually, and several methods, including medications, are used for its management; glucagon-like peptide-1 receptor agonists (GLP-1RAs) are one such class of medications. The efficacy and safety of GLP-1RAs in treating type 2 diabetes mellitus (T2DM) have been assessed and have been shown to significantly improve time in range (TIR) in several clinical trials. However, presently, there is a lack of real-world evidence on the efficacy of GLP-1RAs in improving TIR...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38513615/a-sympathetic-brake-on-gut-glp-1-release
#28
JOURNAL ARTICLE
Antonio J López-Gambero, Victor Jouque, Daniela Cota
The brain-gut neurocircuitry is proving to be finely involved in a wide range of physiological functions. In this issue of Neuron, Ren et al.1 show that adrenergic signaling suppresses postprandial glucagon-like peptide 1 (GLP-1) secretion. This, in turn, raises circulating glucose levels and impairs brain glucose uptake and cognitive function.
March 20, 2024: Neuron
https://read.qxmd.com/read/38512644/combination-therapy-of-endoscopic-gastric-remodeling-with-glp-1ra-for-the-treatment-of-masld
#29
JOURNAL ARTICLE
Pichamol Jirapinyo, Aunchalee Jaroenlapnopparat, Stephen D Zucker, Christopher C Thompson
PURPOSE: The mainstay of treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) is weight loss. Endoscopic gastric remodeling (EGR) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are effective weight loss therapies. This study aims to assess the effect of combining EGR with GLP-1RA on liver-related outcomes and weight profile. MATERIALS AND METHODS: This is a retrospective study of a prospectively collected registry of patients with MASLD and compensated advanced chronic liver disease (cACLD) who underwent EGR...
March 21, 2024: Obesity Surgery
https://read.qxmd.com/read/38512540/real-world-outcomes-of-individualized-targeted-therapy-with-insulin-glargine-300%C3%A2-units-ml-in-insulin-na%C3%A3-ve-korean-people-with-type%C3%A2-2-diabetes-tobe-study
#30
JOURNAL ARTICLE
Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang
INTRODUCTION: The TOujeo BEyond glucose control (TOBE) study evaluated clinical outcomes with insulin glargine 300 units/mL (Gla-300) in insulin-naïve Korean people with type 2 diabetes mellitus (T2DM) in a real-world setting. METHODS: This 24-week, prospective, non-interventional, multicenter, open-label, single-arm, observational study included adults aged ≥ 20 years with T2DM suboptimally controlled with oral hypoglycemic agents and/or glucagon-like peptide 1 receptor agonists who require basal insulin...
March 21, 2024: Advances in Therapy
https://read.qxmd.com/read/38511418/the-role-of-glucagon-like-peptide-1-receptor-agonists-in-metabolic-dysfunction-associated-steatohepatitis
#31
REVIEW
Manal F Abdelmalek, Stephen A Harrison, Arun J Sanyal
Despite its considerable and growing burden, there are currently no Food and Drug Administration-approved treatments for metabolic dysfunction-associated steatotic liver disease or its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). Several glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other agents are in various phases of clinical development for use in MASH; an ideal therapy should reduce liver fat content, improve chronic liver disease, help mitigate metabolic comorbidities and decrease all-cause mortality...
March 21, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38511400/gut-hormones-and-appetite-regulation
#32
JOURNAL ARTICLE
So-Hyeon Hong, Kyung Mook Choi
PURPOSE OF REVIEW: Various gut hormones interact with the brain through delicate communication, thereby influencing appetite and subsequent changes in body weight. This review summarizes the effects of gut hormones on appetite, with a focus on recent research. RECENT FINDINGS: Ghrelin is known as an orexigenic hormone, whereas glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK), postprandial peptide YY (PYY), and oxyntomodulin (OXM) are known as anorexigenic hormones...
March 22, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38511325/novel-angiogenesis-role-of-glp-1-32-36-to-rescue-diabetic-ischemic-lower-limbs-via-glp-1r-dependent-glycolysis-in-mice
#33
JOURNAL ARTICLE
Yikai Zhang, Shengyao Wang, Qiao Zhou, Yi Xie, Yepeng Hu, Weihuan Fang, Changxin Yang, Zhe Wang, Shu Ye, Xinyi Wang, Chao Zheng
BACKGROUND: Restoring the capacity of endothelial progenitor cells (EPCs) to promote angiogenesis is the major therapeutic strategy of diabetic peripheral artery disease. The aim of this study was to investigate the effects of GLP-1 (glucagon-like peptide 1; 32-36)-an end product of GLP-1-on angiogenesis of EPCs and T1DM (type 1 diabetes) mice, as well as its interaction with the classical GLP-1R (GLP-1 receptor) pathway and its effect on mitochondrial metabolism. METHODS: In in vivo experiments, we conducted streptozocin-induced type 1 diabetic mice as a murine model of unilateral hind limb ischemia to examine the therapeutic potential of GLP-1(32-36) on angiogenesis...
March 21, 2024: Arteriosclerosis, Thrombosis, and Vascular Biology
https://read.qxmd.com/read/38511218/anti-diabetic-properties-of-brewer-s-spent-yeast-peptides-in-vitro-in-silico-and-ex-vivo-study-after-simulated-gastrointestinal-digestion
#34
JOURNAL ARTICLE
Marilin E Aquino, Silvina R Drago, Fermín Sánchez de Medina, Olga Martínez-Augustin, Raúl E Cian
Brewer's spent yeast (BSY) hydrolysates are a source of antidiabetic peptides. Nevertheless, the impact of in vitro gastrointestinal digestion of BSY derived peptides on diabetes has not been assessed. In this study, two BSY hydrolysates were obtained ( H1 and H2 ) using β-glucanase and alkaline protease, with either 1 h or 2 h hydrolysis time for H1 and H2 , respectively. These hydrolysates were then subjected to simulated gastrointestinal digestion (SGID), obtaining dialysates D1 and D2 , respectively...
March 21, 2024: Food & Function
https://read.qxmd.com/read/38509913/functional-reorganization-of-memory-processing-in-the-hippocampus-is-associated-with-neuroprotector-glp-1-levels-in-type-2-diabetes
#35
JOURNAL ARTICLE
Nádia S Canário, Joana Crisóstomo, Carolina Moreno, João V Duarte, Isabel C Duarte, Mário J Ribeiro, Beatriz Caramelo, Leonor V Gomes, Paulo Matafome, Francisco P Oliveira, Miguel Castelo-Branco
Type 2 diabetes (T2D) often impairs memory functions, suggesting specific vulnerability of the hippocampus. In vivo neuroimaging studies relating encoding and retrieval of memory information with endogenous neuroprotection are lacking. The neuroprotector glucagon-like peptide (GLP-1) has a high receptor density in anterior/ventral hippocampus, as shown by animal models. Using an innovative event-related fMRI design in 34 participants we investigated patterns of hippocampal activity in T2D (n = 17) without mild cognitive impairment (MCI) versus healthy controls (n = 17) during an episodic memory task...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38509775/optimized-strategy-among-diet-exercise-and-pharmacological-interventions-for-nonalcoholic-fatty-liver-disease-a-network-meta-analysis-of-randomized-controlled-trials
#36
REVIEW
Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong
BACKGROUND: Emerging treatment methods, including exercise, diet, and drugs, for nonalcoholic fatty liver disease have been proposed. However, the differences in their efficacy have not been determined. We aimed to compare the effects of these treatments excluding surgery via a systematic review and network meta-analysis of randomized controlled trials. DATA SOURCE: The data sources included PubMed, Embase, Web of Science and Cochrane up to February 1st, 2023. The endpoints consisted of body mass index (BMI), serum markers of metabolism and liver injury markers, liver fat content, and stiffness...
March 21, 2024: Obesity Reviews
https://read.qxmd.com/read/38509558/liraglutide-improved-the-reproductive-function-of-obese-mice-by-upregulating-the-testicular-ac3-camp-pka-pathway
#37
JOURNAL ARTICLE
Ruibing Qi, Yuzhen Liang, Jinming Yu, Bing Chen, Jiaqin Jiang, Xingye Wu, Wensheng Lu, Zhengming Li
BACKGROUND: The incidence of male reproductive dysfunction is increasing annually, and many studies have shown that obesity can cause severe harm to male reproductive function. The mechanism of male reproductive dysfunction caused by obesity is unclear, and there is no ideal treatment. Identification of effective therapeutic drugs and elucidation of the molecular mechanism involved in male reproductive health are meaningful. In this study, we investigated the effects of the GLP-1 receptor agonist liraglutide on sex hormones, semen quality, and testicular AC3/cAMP/PKA levels in high-fat-diet-induced obese mice...
March 20, 2024: Reproductive Biology and Endocrinology: RB&E
https://read.qxmd.com/read/38509342/microfluidic-based-systems-for-the-management-of-diabetes
#38
REVIEW
Shuyu Zhang, Anne E Staples
Diabetes currently affects approximately 500 million people worldwide and is one of the most common causes of mortality in the United States. To diagnose and monitor diabetes, finger-prick blood glucose testing has long been used as the clinical gold standard. For diabetes treatment, insulin is typically delivered subcutaneously through cannula-based syringes, pens, or pumps in almost all type 1 diabetic (T1D) patients and some type 2 diabetic (T2D) patients. These painful, invasive approaches can cause non-adherence to glucose testing and insulin therapy...
March 20, 2024: Drug Delivery and Translational Research
https://read.qxmd.com/read/38508100/exploring-the-association-between-suicidal-thoughts-self-injury-and-glp-1-receptor-agonists-in-weight-loss-treatments-insights-from-pharmacovigilance-measures-and-unmasking-analysis
#39
JOURNAL ARTICLE
A Guirguis, S Chiappini, G D Papanti P, R Vickers-Smith, D Harris, J M Corkery, D Arillotta, G Floresta, G Martinotti, F Schifano
INTRODUCTION: The study addresses concerns about potential psychiatric side effects of Glucagon-like peptide-1 receptor agonists (GLP-1 RA). AIM: The aim of this work was to analyse adverse drug reports (ADRs) from the Food and Drug Administration Adverse Events Reporting System (FAERS) using metformin and orlistat as comparators. METHODS: Descriptive and pharmacovigilance disproportionality analyses was performed. RESULTS: A total of 209,354 ADRs were reported, including 59,300 serious cases...
March 19, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38508074/white-analytical-insight-for-sensitive-fluorescent-determination-of-semaglutide-and-tirzepatide-in-pharmaceuticals-and-biological-matrices
#40
JOURNAL ARTICLE
Noura M Mansour, Amal A El-Masry, Dina T El-Sherbiny, Mohamed A Moustafa
The present study is focused on the sensitive determination of newly FDA-approved glucagon-like-peptide agonists semaglutide (SEM) and tirzepatide (TIR). Direct, selective and label-free spectrofluorometric method was proposed and validated (according to ICH guidelines) for determination SEM and TIR in their pure form, newly approved pharmaceuticals and spiked human plasma. The developed method was based on measuring the native fluorescence of SEM and TIR in ethanol at 294.8 and 303 nm after being excited at 216 and 225 nm for SEM and TIR in order...
March 15, 2024: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
keyword
keyword
67329
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.